The history of Viagra presents a complex picture for those considering investment. While the initial release generated significant returns, the expiration of its exclusive rights opened the floodgates to generic alternatives, dramatically reducing sales. This presents a specific dilemma for drug manufacturers banking on comparable blockbuster medic

The story of Viagra, and its parent company copyright, presents a challenging case study for investors. Originally a blockbuster drug, yielding billions in revenue , its intellectual property lapse created a deluge of generic competition , significantly impacting its dominance. While specific firms may seek to capitalize on similar conditions , the